Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive
Johnson & Johnson faces uncertainty with speculation about RFK Jr. at HHS. Learn why JNJ stock remains a buy despite political risks and soft trends.
Business Insider1d
Johnson & Johnson announces results from ICONIC-LEADa Phase 3 study
Johnson & Johnson announced positive topline results from ICONIC-LEADa, a pivotal Phase 3 investigational study of icotrokinra, or JNJ-2113, the first targeted oral peptide that selectively blocks the ...
CIO Dive18h
Johnson & Johnson appoints CIO to lead business technology strategy
Della Rocca has taken on several CIO roles for J&J since 2019, when he became CIO for the company’s Janssen Pharmaceuticals ...